Table 4. Relevant clinical trials studying the effects of regadenoson on reactive airway diseases.

FEV1: Forced expiratory volume 1; COPD: Chronic obstructive pulmonary disease

Authors	Design	Sample size	Primary outcome	Results
Thomas et al. [29]	Randomized, double-blinded placebo-controlled crossover trial	49 COPD Patients	Decline in FEV1	No difference between both groups
Leaker et al. [30]	Randomized, double-blinded placebo-controlled crossover trial	48 Asthma Patients	Decline in FEV1	No difference between both groups
Prenner et al. [31]	Randomized, double-blind placebo-controlled study	576 Asthma Patients	Decline in FEV1	No difference between both groups
Prenner et al. [31]	Randomized, double-blind placebo-controlled study	467 COPD Patients	Decline in FEV1	No difference between both groups